Microbix Biosystems Inc. Initiates Share Repurchase Program
Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF) is excited to announce the initiation of its Normal Course Issuer Bid (NCIB) program, aimed at repurchasing and cancelling outstanding common shares. This strategic move reinforces Microbix’s commitment to enhancing shareholder value, as the company focuses on its long-term growth and viability in the life sciences sector.
Understanding the Normal Course Issuer Bid
The NCIB provides Microbix the ability to repurchase up to 6,949,346 common shares, representing approximately five percent of the 138,986,931 shares outstanding as of the most recent reporting date. This program is set to commence on December 9, 2025, and will conclude on December 8, 2026, unless completed earlier. The precise number of shares to be repurchased will be determined by the company’s management in alignment with applicable regulations and market conditions.
Board Approval and Market Execution
The NCIB has received the necessary approvals from Microbix’s Board of Directors and will comply with all relevant rules and policies dictated by the Toronto Stock Exchange (TSX) and Canadian securities laws. Shares repurchased will occur through open market transactions or other authorized means, allowing Microbix to buy back shares at the prevailing market price at that time.
Daily Purchase Limits and Previous NCIB Performance
Under TSX regulations, the maximum number of shares that can be repurchased in any single day is limited to 20,339. This number is calculated based on the average daily trading volume (ADTV) from the preceding six months. It’s noteworthy that Microbix previously executed a NCIB spanning December 9, 2024, to December 8, 2025, during which it successfully repurchased 3,661,581 shares at an average price of $0.369.
Strategic Planning and Corporate Funds
Microbix has established a pre-defined automatic securities purchase plan with its broker, Ventum Financial Corp., which will facilitate share repurchases during internal trading blackout periods and other restricted times. This meticulous planning ensures that the company can effectively manage its repurchase strategy while adhering to regulatory standards. Moreover, the timing of these buybacks will be guided by management's assessment of market conditions and share prices, ensuring decisions are informed and beneficial.
Enhancing Shareholder Equity
The Board of Directors believes that Microbix’s intrinsic value is not currently reflected in the market price of its shares. As a proactive measure, the NCIB aims to optimize the use of corporate funds and amplify the stakeholders' equity interest by reducing the total number of shares outstanding through repurchases. This strategy is expected to capture the attention of investors and potentially boost the market perception of Microbix.
A Glance at Microbix Biosystems Inc.
Microbix Biosystems Inc. is a leading innovator in the life sciences space, specializing in the production of proprietary biological products that cater to human health. The company employs over 120 skilled professionals and has reported revenues of C$25.4 million in its latest financial year. Among its extensive product lineup, Microbix manufactures critical ingredients and devices geared towards the global diagnostics market, including immunoassay antigens and laboratory quality assessment products.
Microbix continues to broaden its impact in the biomedical field through innovation, as its products provide essential support for clinical laboratory proficiency testing, assay development, and maintaining quality within diagnostic workflows. The company’s offerings, such as QAPs™ and QUANTDx™, are now available in over 30 countries, underscored by a robust network of international distributors.
Innovative Product Development
In addition to diagnostics, Microbix applies its expertise to develop advanced biological products, such as Kinlytic® urokinase, which is utilized as a thrombolytic drug for treating blood clots. The company also produces reagents specifically designed to enhance diagnostic testing efficacy, further solidifying its role as a distinguished player in the life sciences arena.
Frequently Asked Questions
What is the purpose of the Normal Course Issuer Bid?
The NCIB allows Microbix to repurchase shares to enhance shareholder value, reflecting the company's confidence in its long-term growth potential.
How many shares can Microbix repurchase under the NCIB?
Microbix is authorized to repurchase up to 6,949,346 common shares, which is about five percent of its outstanding shares.
What are the daily limits on share repurchases?
The maximum number of shares Microbix can repurchase in a single day is capped at 20,339, based on the average daily trading volume.
How does Microbix determine the timing of share repurchases?
Timing decisions are guided by market conditions, share price, and the availability of cash, with input from management to optimize the strategy.
What are some key products offered by Microbix?
Microbix specializes in diagnostic antigens, lab quality assessment products, and proprietary drugs like Kinlytic® urokinase, among others.
